Примери за използване на To prescribe or use на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The MAH shall ensure that all healthcare professionals who are expected to prescribe or use Provenge are provided with the following items.
The company that markets Eurartesim will provide all doctors expected to prescribe or use Eurartesim with an educational pack containing important information on the correct use of the medicine, including a checklist of the medicines that Eurartesim must not be given with, to reduce the risk of QTc interval prolongation.
The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Vibativ a health care professional educational pack.
This information must not under any circumstances be used to diagnose an illness or a physical problem, or to prescribe or use medications.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Victrelis are provided with a healthcare professional educational pack containing the following at.
You should not use the information contained herein for diagnosing any illness or physical problem or as distance treatment or in order to prescribe or use any medication presented on the Site.
The Member States shall ensure that all physicians who are expected to prescribe or use Colobreathe are provided with a healthcare professional and patient educational pack containing the following.
The MAH shall ensure that in each Member State where Kineret is marketed, all healthcare professionals andpatients/caregivers who are expected to prescribe or use Kineret have access to/are provided with the following educational package.
The company that makes Viread will ensure that all doctors who are expected to prescribe or use Viread in children are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
The MAH shall ensure that in each Member State where XELJANZ is marketed, all healthcare professionals andpatients/carers who are expected to prescribe or use XELJANZ have access to/are provided with the following educational package.
The company that markets Vibativ will ensure all doctors who are expected to prescribe or use Vibativ receive a letter and an educational pack containing the summary of product characteristics, package leaflet and a guide setting out important safety information on the correct use of Vibativ.
The Member States shall ensure that the MAH provides to all physicians who are expected to prescribe or use INCIVO a healthcare professional educational pack containing the following.
The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Vibativ a Direct Healthcare Professional Communication letter, the text of which is appended to the CHMP assessment report.
The Marketing Authorisation Holder shall ensure that at launch andafter launch all physicians who are expected to prescribe or use Valdoxan are provided with the updated educational material containing the following.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Colobreathe are provided with a healthcare professional and patient educational pack containing the following.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Eurartesim are provided with a healthcare profession educational pack containing the following.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use INCIVO are provided with a healthcare professional educational pack containing the following.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Vibativ are provided with a healthcare professional educational pack containing the following.
The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Tamiflu a Direct Healthcare Professional Communication(DHPC) letter, the text of which is appended to the CHMP assessment report.
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Valdoxan, are provided with patient booklets to be distributed to their patients being prescribed this medicine.
The company that markets Tenofovir disoproxil Zentiva will ensure that all doctors who are expected to prescribe or use the medicine are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
In addition, the company that makes Vimizim must ensure that all healthcare professionals expected to prescribe or use the medicine are provided with educational material, informing them of how the medicine should be used and the risk of severe allergic reactions.
The MAH must ensure that all healthcare professionals andpatients/carers who are expected to prescribe and/or use JINARC have access to/are provided with the following educational package.
The MAH shall ensure that in each MS where Myfenax is marketed, all healthcare professionals andpatients who are expected to prescribe, dispense or use Myfenax are provided with the following educational package.
The MAH shall ensure that in each MS where Mycophenolate mofetil Teva is marketed, all healthcare professionals andpatients who are expected to prescribe, dispense or use Mycophenolate mofetil Teva are provided with the following educational package.
The MAH shall ensure that in each Member State where sotagliflozin is marketed, all healthcare professionals andpatients/carers who are expected to prescribe, dispense or use the product have access to: .
The MAH shall ensure that in each Member State where VPRIV is marketed, all healthcare professionals andpatients/carers who are expected to prescribe, dispense or use VPRIV have access to/are provided with the following educational package.
The MAH shall ensure that in each Member State where RINVOQ is marketed, all healthcare professionals andpatients/carers who are expected to prescribe, dispense or use RINVOQ have access to/are provided with the following educational package.
The MAH shall ensure that in each Member State where dapagliflozin is marketed for type 1 diabetes, all healthcare professionals andpatients/carers who are expected to prescribe, dispense or use the product have access to: .
The MAH shall ensure that in each Member State where Sialanar is marketed, all healthcare professionals andpatients/carers who are expected to prescribe, dispense or use Sialanar have access to or are provided with the following educational packages.